HUP0003885A2 - Készítmény pangásos szívelégtelenség kezelésére - Google Patents

Készítmény pangásos szívelégtelenség kezelésére Download PDF

Info

Publication number
HUP0003885A2
HUP0003885A2 HU0003885A HUP0003885A HUP0003885A2 HU P0003885 A2 HUP0003885 A2 HU P0003885A2 HU 0003885 A HU0003885 A HU 0003885A HU P0003885 A HUP0003885 A HU P0003885A HU P0003885 A2 HUP0003885 A2 HU P0003885A2
Authority
HU
Hungary
Prior art keywords
moxonidine
composition
hours
active ingredient
patients
Prior art date
Application number
HU0003885A
Other languages
English (en)
Hungarian (hu)
Inventor
John L. McNay
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0003885A2 publication Critical patent/HUP0003885A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0003885A 1996-06-06 1997-06-05 Készítmény pangásos szívelégtelenség kezelésére HUP0003885A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (1)

Publication Number Publication Date
HUP0003885A2 true HUP0003885A2 (hu) 2001-04-28

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003885A HUP0003885A2 (hu) 1996-06-06 1997-06-05 Készítmény pangásos szívelégtelenség kezelésére

Country Status (17)

Country Link
EP (1) EP0914128A1 (cs)
JP (1) JP2000511906A (cs)
KR (1) KR20000016406A (cs)
CN (1) CN1226166A (cs)
AU (1) AU3233197A (cs)
BR (1) BR9709546A (cs)
CA (1) CA2256720A1 (cs)
CZ (1) CZ397698A3 (cs)
EA (1) EA199900006A1 (cs)
HU (1) HUP0003885A2 (cs)
IL (1) IL126966A0 (cs)
NO (1) NO985695L (cs)
PL (1) PL330637A1 (cs)
TR (1) TR199802496T2 (cs)
WO (1) WO1997046241A1 (cs)
YU (1) YU55998A (cs)
ZA (1) ZA974978B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
EP1150680B1 (de) * 1999-02-01 2005-01-12 Solvay Pharmaceuticals GmbH Verwendung von moxonidin zur behandlung nach herzinfarkt
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
ZA974978B (en) 1998-12-07
CZ397698A3 (cs) 1999-05-12
EP0914128A1 (en) 1999-05-12
TR199802496T2 (xx) 1999-02-22
KR20000016406A (ko) 2000-03-25
JP2000511906A (ja) 2000-09-12
EA199900006A1 (ru) 1999-06-24
BR9709546A (pt) 1999-08-10
CA2256720A1 (en) 1997-12-11
PL330637A1 (en) 1999-05-24
CN1226166A (zh) 1999-08-18
AU3233197A (en) 1998-01-05
YU55998A (en) 1999-11-22
NO985695D0 (no) 1998-12-04
WO1997046241A1 (en) 1997-12-11
IL126966A0 (en) 1999-09-22
NO985695L (no) 1999-02-04

Similar Documents

Publication Publication Date Title
JP3776931B2 (ja) Ａｃｅ阻害剤ラミプリルとジヒドロピリジン化合物を含有する新規医薬組成物
RU2346703C2 (ru) Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний
KR101181172B1 (ko) 방출성이 제어된 시간차 투여 약제학적 제제
US7741374B1 (en) Methods of use of fenofibric acid
US20100215737A1 (en) Combination pharmaceutical compositions
JP2005512997A (ja) タムスロシン錠
TW201038300A (en) Galenic formulations of organic compounds
CN111886003A (zh) 包含依折麦布和瑞舒伐他汀的药物组合制剂
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
HUP0003885A2 (hu) Készítmény pangásos szívelégtelenség kezelésére
EA030466B1 (ru) Фармацевтическая композиция, обладающая улучшенной стабильностью
HU231052B1 (hu) Bisoprololt és ramiprilt tartalmazó stabil kombinációs gyógyszerkészítmény
JP6157740B2 (ja) 徐放性メトホルミンと速放性ＨＭＧ−ＣｏＡ還元酵素阻害剤を含む複合製剤
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
JP2008515903A (ja) 拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用
BRPI0810697A2 (pt) formulações orais de liberação controlada de compostos de modulação de canal de íon e métodos relacionados à prevenção de arritmia
MXPA98010056A (en) Formulation and method for dealing with insufficienciacardiac, congest
US20100008956A1 (en) Composition and combinations of carboxylic acid losartan in dosage forms
KR102924710B1 (ko) 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법
TW201725038A (zh) 藉由曲線下面積（ａｕｃ）給與奧美沙坦（ｏｌｍｅｓａｒｔａｎ）之劑量的方法
RU2543637C2 (ru) Пролонгированная фармацевтическая композиция гипотензивного действия и способ ее изготовления
KR20190107838A (ko) 이바브라딘의 서방성 약제학적 조성물 및 이의 제조방법
Wang Optimisation of once-a-day oral sustained-release formulations for the novel antihypertensive drug MT-1207
WO2007010509A2 (en) Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist